Skip to content

A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates. - Strontium following bisphosphonate therapy

A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates. - Strontium following bisphosphonate therapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003138-16-GB
Enrollment
120
Registered
2005-07-25
Start date
2005-08-26
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteoporosis MedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal

Interventions

Trade Name: Protelos Product Name: strontium ranelate Product Code: n/a Pharmaceutical Form: Oral suspension

Sponsors

R+ D department, Hull and East Yorkshire NHS Hospital Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) - Age: 50-75 2) - T score: 1 year treatment with oral bisphosphonates and stopped treatment within the last 1 month due to lack of effect or side effects. Also if treated with pamidronate for > 1 year and last infusion within the last 3 month. (to allow clear distinction between the study groups) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Significant renal disease. (creatinine clearance < 30 ml/min) Prior treatment with Strontium Ranelate. Active malignancy Osteomalacia Primary hyperparathyroidism Patient is unable to give informed consent

Design outcomes

Primary

MeasureTime frame
Main Objective: Assessing whether previous treatment of osteoporosis with a bisphosphonates affects the subsequent response to treatment with Strontium Ranelate. ; Secondary Objective: Assessment of the relative merits of different established techniques for monitoring the response of osteoporotic patients to Strontium Ranelate. ; Primary end point(s): The change from baseline in bone mineral density at 1 year will be compared between the 2 groups. At the end of the first year subjects will be offered the chance to enter into the second year of the study. Informed consent will be taken for the second year. The drug treatment will remain the same but there will be 2 extra vists at 18 and 24 months. The end point for this extention will be bone mineral density at year 2 compared between the 2 groups.

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026